checkAd

    DGAP-News  108  0 Kommentare DEFENCE THERAPEUTICS ACHIEVES A MAJOR MILESTONE AND BEGINS IND-ENABLING TESTING OF ITS ACCUTOX LEAD COMPOUND AGAINST BREAST CANCER

    DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous
    DEFENCE THERAPEUTICS ACHIEVES A MAJOR MILESTONE AND BEGINS IND-ENABLING TESTING OF ITS ACCUTOX LEAD COMPOUND AGAINST BREAST CANCER

    10.01.2022 / 13:30
    The issuer is solely responsible for the content of this announcement.


    CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE

    DEFENCE THERAPEUTICS ACHIEVES A MAJOR MILESTONE AND BEGINS IND-ENABLING TESTING OF ITS ACCUTOX LEAD COMPOUND AGAINST BREAST CANCER

    Vancouver, BC, Canada, January 10th, 2022 - Defence Therapeutics Inc. ("Defence" or the "Company"), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the start of its final step in GLP studies on its lead anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited prior to initiate its Phase I trial in breast cancer patients.

    Eurofins Advinus Limited is a leading Drug Discovery and Development Contract Research Organization (CRO) with 30 years of experience testing regulated products under Good Laboratory Practice (GLP). With 400 employees, 80 full Preclinical IND packages completed and over 20,000 GLP Toxicology studies with the full range of required toxicology studies, Eurofins Advinus is one of the most experienced Drug Development Contract Research Organisation.

    Eurofins has been mandated by Defence to complete all final GLP studies required by the FDA and Health Canada on its lead AccuTOXTM molecule. The studies will be conducted on both rats (rodent) and dogs (non-rodents) to identify the maximum tolerated dose in addition to evaluate the pharmacokinetic and toxicology profile of the lead compound.

    "We are pleased with our very efficient advancement in the AccuTOXTM program. Not only did the AccumTM elicit powerful anti-cancer properties, but in addition we screened a series of variants (>50) to identify the lead AccuTOXTM molecule capable of efficiently killing more than 9 different tumor cell lines of both murine and human origin (lymphoma, melanoma, breast, colon and non-small cell lung carcinoma). Completing this set of GLP studies represents therefore the final step before approaching the FDA/Health Canada to initiate a Phase I trial in breast cancer patients in 2022", says Mr. Plouffe, the CEO of Defence.

    Seite 1 von 3


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News DEFENCE THERAPEUTICS ACHIEVES A MAJOR MILESTONE AND BEGINS IND-ENABLING TESTING OF ITS ACCUTOX LEAD COMPOUND AGAINST BREAST CANCER DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE THERAPEUTICS ACHIEVES A MAJOR MILESTONE AND BEGINS IND-ENABLING TESTING OF ITS ACCUTOX LEAD COMPOUND AGAINST BREAST CANCER 10.01.2022 / 13:30 The issuer is solely …

    Schreibe Deinen Kommentar

    Disclaimer